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Abstract MicroRNAs (miRNAs) are small non-coding
RNAs that regulate a variety of biological processes. Cell-
free miRNAs detected in blood plasma are used as specific
and sensitive markers of physiological processes and some
diseases. Circulating miRNAs are highly stable in body fluids,
for example plasma. Therefore, profiles of circulatingmiRNAs
have been investigated for potential use as novel, non-invasive
anti-doping biomarkers. This review describes the biological
mechanisms underlying the variation of circulating miRNAs,
revealing that they have great potential as a new class of
biomarker for detection of doping substances. The latest de-
velopments in extraction and profiling technology, and the
technical design of experiments useful for anti-doping, are also
discussed. Longitudinal measurements of circulating miRNAs
in the context of the athlete biological passport are proposed as
an efficient strategy for the use of these new markers. The
review also emphasizes potential challenges for the translation
of circulatingmiRNAs from research into practical anti-doping
applications.
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Introduction
A major challenge in anti-doping is identification of specific
and sensitive non-invasive biomarkers that can be routinely
measured in easily accessible samples. MicroRNAs (miRNAs)
are a particularly promising class of biomarker. miRNAs are
small (19–25 nucleotides), non-encoding RNAs that enable
post-transcription regulation of gene expression by suppres-
sion of specific target messenger RNAs (mRNAs) [1]. Since
their discovery in the early 1990s, these small molecules have
been revealed to have important regulatory functions in a wide
range of biological and pathological processes. To date, more
than 1800 miRNAs have been identified in humans [2]. The
number of miRNAs in our species therefore seems to be
smaller than the number of conventional mRNAs, estimated
to be 30,000 [3].
Since 2008, miRNAs have been detected in serum, plas-
ma, urine, saliva, and other body fluids [4]. Although most
RNA molecules are unstable, circulating miRNAs are high-
ly stable and readily detectable. Cell-free miRNAs in body
fluids are stable under harsh conditions, including boiling,
low and high pH, extended storage, and multiple freeze–
thaw cycles [5]. In contrast, synthetic or purified miRNAs
added to serum or plasma are quickly degraded by high
levels of RNase activity in plasma [6]. Thus, circulating
miRNAs are not intrinsically resistant to endogenous RNase
activity.
Stability of circulating miRNAs
The molecular basis of the high stability of circulating
miRNAs has been investigated in different laboratories. One
hypothesis suggests that circulating miRNAs are protected by
microvesicles, for example exosomes and microparticles; al-
ternatively, circulating miRNAs may be associated with spe-
cific protective proteins.
Recently, different groups have found that most circulating
miRNAs co-fractionate with protein complexes [6, 7]. Arroyo
et al. [6] found that miRNAs are sensitive to protease
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treatment of plasma, indicating that protein complexes pro-
tect circulating miRNAs from plasma RNases. Investigation
of the protective protein complexes revealed that Argonaute
2 (Ago2), a protein component of the RNA-induced silenc-
ing complex, is present in human plasma and elutes with
plasma miRNAs in size-exclusion chromatography [6, 8].
The extracellular stability of Ago2–miRNA complexes has
also been observed in cell culture. Both Ago2 protein and
miRNAs remain stable for several weeks in cell lysates,
even in the absence of protease inhibitors [7]. Immunopre-
cipitation assays performed on plasma revealed that Ago2
readily recovers non-vesicle-associated plasma miRNAs. In
these studies, most miRNAs tested co-purified with the
Ago2 ribonucleoprotein complex; however, only a minority
of specific miRNAs were associated with vesicles [6].
These observations revealed the existence of two popula-
tions of circulating miRNAs, and suggested that circulating
Ago2 complexes are most probably the reason for the
stability of plasma miRNAs [6, 7]. These studies have
important implications for the development of biomarker
approaches based on sampling and analysis of circulating
miRNAs.
Secretion mechanism and origin of circulating miRNAs
The presence of miRNAs in the extracellular environment
has led researchers to develop two main hypotheses regard-
ing systems for miRNA export from cells and tissues [9].
One hypothesis is that all types of circulating miRNA in
biological fluid are by-products of cellular activity and cell
death [7]. This “by-product release” hypothesis could ex-
plain multiple observations that, after toxicity occurs in
some tissues, the levels of miRNAs specific for the affected
tissue increase in the plasma [10–12]. The other hypothesis
is that secretion of miRNAs is caused by an increase in
cellular activity leading to the release of miRNAs, either in
Ago2–miRNA complexes or, for a minority of miRNAs,
packaged in microvesicles, for example exosomes.
Recently, more attention has been devoted to under-
standing the origin of circulating miRNAs and its effect
on biomarker specificity [9, 13, 14]. Because blood
cells are in extensive contact with plasma, they should
be major contributors to the extracellular miRNA con-
tent of plasma [15, 16]. This idea is supported by
observations that perturbations in blood-cell counts and
haemolysis can alter plasma miRNAs; furthermore, ul-
tracentrifugation steps that remove intact cells and de-
bris reduce the level of miRNAs in plasma [16]. How-
ever, because tissue-specific mRNAs from liver, muscle,
heart, brain, lungs, and placenta have been detected in
plasma [10–13, 17], it is probable that other organs
contribute to extracellular miRNA. Many groups have
observed that tumours secrete miRNAs, and have de-
tected cancer tissue-specific miRNAs in the circulatory
system [18]. These observations support the theory that
circulating blood cells are not the only source of circu-
lating miRNAs.
Circulating miRNAs as disease biomarkers
In healthy individuals levels of cell-free miRNAs present in
serum are stable, and the plasma and/or serum miRNA profile
is similar to that of circulating blood cells. Altered serummiRNA
levels may be indicative of physiological or pathological
changes, and might therefore be used as surrogate biomarkers.
Lawrie et al. were the first to discover tumour-specific
deregulation of circulatingmiRNAs [19]. Their study revealed
that miR-21 is abundant in the sera of diffuse large B-cell
lymphoma patients. Since then, many other investigations
have revealed the diagnostic and prognostic value of measur-
ing miRNAs in body fluids in the context of a variety of solid
cancers [20, 21]. In 2008, Mitchell et al. reported that
miRNAs derived from epithelial tumours are also rapidly
released into the bloodstream [5]. Shen et al. [22] revealed
that plasma miRNA expression profiles could be useful for
discriminating non-small cell lung cancer (NSCLC) patients
from healthy controls and patients with chronic obstructive
pulmonary disease (COPD).
Regarding non-neoplastic changes, tissue-specific miRNAs
have been analysed in the bloodstream as markers of myocar-
dial [11] and liver injury [12]. For example, myocardial infarc-
tion induced an increase in the plasma level of miR-133a, a
muscle-specific miRNA [23]. Several studies have revealed
that liver injury is associated with increased plasma levels of
miR-122 and miR-192 [12].
Physiological changes, for example pregnancy, increase
the level of several miRNAs in plasma [13]. miR-517a and
miR-526a undergo substantial changes that could be used to
distinguish pregnant from non-pregnant women with high
accuracy.
Circulating miRNAs as anti-doping biomarkers
In the same way that some biomarkers are used to detect the
biological signs of disease, doping biomarkers have been used
for some time in anti-doping tests to detect the biological signs
of doping. The potential of circulating miRNAs for use as
specific anti-doping biomarkers has been revealed by our
laboratory and others. We found that plasma miRNA expres-
sion profiles can be useful in detecting erythropoiesis-
stimulating agents (ESA) [24]. That study revealed that levels
of a specific circulating miRNA, miR-144, increase in plasma
samples after a single methoxy polyethylene glycol-epoetin
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beta (Mircera) injection. This miRNA has been reported to be
essential for erythropoiesis in a variety of organisms, and our
finding revealed the potential of miRNAs as circulating bio-
markers for ESA detection. Another study revealed that cir-
culating miRNAs could be used as biomarkers to detect
recombinant human growth hormone (rhGH) abuse: Kelly
and colleagues identified and confirmed four miRNAs that
were differently expressed in all individuals using therapeutic
replacement doses of rhGH, relative to normal controls or
individuals with naturally high levels of GH [25].
Recently, we found that circulating miRNAs could be used
to detect autologous blood transfusion [26]. Transfusion of
autologous blood induced an increase in the plasma levels of
specific circulating miRNAs compared with a non-transfused
control group. Because blood transfusion causes substantial
changes in miRNA levels in the lung, the origin of these
miRNAs was related to pulmonary tissue. We also observed
partial suppression of erythropoietin (EPO) after transfusion.
A combination of miRNAs and EPO measurement in a math-
ematical model increased the efficiency of detection of autol-
ogous transfusion via miRNA analysis.
Methods for analysis of circulating miRNAs
Three matrices have been studied in the context of miRNA
profiling in blood: serum, plasma, and whole blood. The
choice of matrix has been reported to have a significant effect
on miRNA concentration. Serum has lower levels of circulat-
ing miRNAs than plasma [27]. Because of the large number of
blood analyses required for the athlete biological passport
(ABP), EDTA–plasma is the matrix most widely used in
anti-doping. Because blood variables and miRNAs are mea-
sured in the same matrix, a single EDTA–plasma sample
would be sufficient to perform the test, and plasma would
therefore seem to be the best material for miRNA analysis in
anti-doping laboratories. However, plasma samples contain-
ing heparin as an anticoagulant should not be used because
this substance can interfere with subsequent assays, for exam-
ple the reverse transcription reaction of RT–PCR.
One critical factor that might affect the results of miRNA
quantification is the presence of haemolysis. Several studies have
observed that mature erythrocytes contain abundant and diverse
miRNA. In a recent study, Blondal et al. suggested different
procedures and tests for assessment of haemolysis [28]; one
simple and cost-effective way is to use a spectrophotometer
and measure oxyhaemoglobin absorbance at λ=414 nm. Other
methods, based on delta calculation between erythrocyte-
enriched miR-451 and miR-23a, which is not affected by
haemolysis, have been proposed as indicators of haemolysis.
Because of the small amount of circulating miRNA and the
large amount of proteins and lipids, miRNA extraction from
blood samples is technically challenging. Moreover, plasma
and serum contain large amounts of reverse transcription and
PCR inhibitors. To overcome these challenges, several phe-
nol–chloroform-based procedures are available for extracting
miRNA from biological fluid [29].
Most of these methods combine phenol–guanidine-based
lysis of samples and silica-membrane-based purification of
total RNA (Fig. 1). The lysis reagent is a solution of phenol
and guanidine thiocyanate, designed to facilitate lysis, to de-
nature protein complexes and RNases, and to remove most of
the residual DNA and proteins from the lysate via organic
extraction. After addition of chloroform, the lysate is separated
into aqueous and organic phases by means of centrifugation.
The aqueous phase is extracted and the sample is then applied
to the silica membrane-based spin column, where the RNA
binds to the membrane but phenol and other contaminants are
efficiently washed away. To increase the efficiency of phenol–
chloroform extraction, Andreasen et al. revealed that addition
of a small carrier RNA before total RNA extraction improved
the yield and reproducibility of separate RNA extractions [29].
Commercially available kits without acid-phase separation
can also be used for isolation of miRNA from body fluids
(Fig. 1). The general principle of extraction is similar to that of
phenol–chloroform extraction, but the non-phenol lysis solu-
tion contains only guanidine thiocyanate, and salt solution is
added to denature and precipitate proteins. The phenol–chlo-
roform procedure yields more miRNA, reduces the variance
between assays [27], and could be fully automated, and this
procedure will therefore usually be the best method for
extracting miRNAs from biofluids. Nevertheless, different
extraction methods should be tested for each study to establish
the optimum procedure.
One of the main problems associated with circulating
miRNA extraction and comparison of collected samples is
quantification of the miRNA. Because the miRNA content of
plasma is low, it can only just be determined by use of spec-
trophotometers. Efficiency of extraction of circulating miRNA
could be assessed by spiking plasma with known quantities of
non-human miRNAs (e.g. that of Caenorhabditis elegans ).
Synthetic spike-in miRNAs should be added to the denatur-
ation buffer (e.g. Trizol or lysis buffer). These miRNAs go
through the entire extraction process and are measured in the
final miRNA eluate by use of qRT–PCR, providing an internal
reference against which to assess the efficiency of extraction.
Addition of synthetic spike-in miRNA can also be used to
assess the reverse transcription reaction.
Profiling new circulating miRNA anti-doping biomarkers
When searching for circulating miRNA-based doping bio-
markers, different profiling methods can be used. Profiling
enables us not only to discover changes in miRNA levels after
treatment, but also to find stable miRNAs that could be used as
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endogenous controls. Technological advances have resulted in
many miRNA-profiling techniques.
High-throughput quantitative reverse transcription (qRT)–
PCR remains the most sensitive and reliable method for
detecting circulating miRNAs. A positive aspect of this ap-
proach is its ease of incorporation into the workflow of labo-
ratories that are already familiar with real-time PCR. For
large-scale miRNA profiling (which involves hundreds of
miRNAs) by use of qRT–PCR, commercially available pre-
plated PCR primers, typically distributed across multi-well
dishes, are available [3]. To prevent variation of primer
hybridisation among the hundreds of PCR assays, locked
nucleic acids (LNA) are incorporated into primers [30].
Microarrays were among the first methods to be used for
parallel analysis of large numbers of miRNAs, and several
variations of the approach have been developed [3]. miRNA
microarrays have the advantage of being less expensive than
other profiling methods. However, several limitations have been
described, including a restricted linear range of quantification,
low sensitivity, and imperfect specificity for some miRNAs.
A deep-sequencing approach has been investigated in sev-
eral studies with the objective of evaluating the potential use of
circulating miRNAs as disease biomarkers [13]. The major
advantages of next-generation sequencing for miRNA profil-
ing are the detection of both novel and already knownmiRNAs
and the precise identification of miRNA sequences. Potential
limitations of next-generation sequencing include high cost,
although this is dropping with the introduction of new instru-
ments and the use of DNA “barcoding”. For example, use of
barcoded adapters enables multiplexing of 20 samples in a
single sequencing reaction, dramatically reducing the cost of
sequencing five million reads per sample to 150 USD [13].
Strategies for identifying circulating miRNA-based
anti-doping biomarkers
In the process of searching for blood miRNA-based doping
biomarkers, a high-throughput RT–qPCR strategy was used to
identify plasma miRNA-based biomarkers for detecting au-
tologous blood transfusion [26]. In this strategy, multiplex
real-time RT–qPCR is used to identify a set of specific circu-
lating miRNAs. RT–qPCR was chosen because it is a faster,
simpler, and more sensitive technique than sequencing or use
of microarrays.
As depicted in Fig. 2, the strategy was separated into several
steps:
1. profiling with pre-plated PCR primers, using subjects
who have undergone treatment including blood transfu-
sion, to find a potential profile of circulating miRNAs and
endogenous controls;
2. individual RT–qPCR validation of selected miRNAs
obtained at every time point before and after doping
intervention (from three days before treatment, D − 3, to
10 days afterward, D + 10);
3. comparison with variations in blood properties; and
4. pre-analytical and analytical characterisation of selected
miRNAs.
In general, initial screening by use of the high-throughput
technique is intended to identify differently expressed plasma
miRNAs in artificially doped volunteers. However, once we
know the specific miRNAs linked to doping, we can directly
determine their levels by use of individual qRT–PCR.
The detection window for the panel of differently
expressed miRNAs from the screening study was determined
Fig. 1 Schematic outline of two
miRNA extraction procedures.
The commercial kit does not use
phenol–chloroform to degrade
protein from plasma samples
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by longitudinal measurement using amaximum number of time
points. The stabilities of non-differently expressed miRNAs at
every time point were also investigated, and were used as
endogenous controls. The screened endogenous controls and
artificial spike-in miRNAs were used for normalisation.
For decades, haematological variables have been common-
ly used as reference values in clinical and anti-doping studies.
For example, haemoglobin has been tested to detect autolo-
gous blood transfusion [31]. Correlation between blood-
marker variables and circulating miRNAs could increase the
efficiency of result interpretation. In our study the combina-
tion of circulating miRNAs and other variables, including
EPO, resulted in greater discriminative power for the detection
of autologous blood transfusion [26].
Providing proof of principle for a reliable miRNA doping
test is a long process. Many pre-analytical and analytical
variables that might affect the measurement of miRNAs in
anti-doping applications have yet to be studied in detail.
McDonald et al. proposed a method for validating circulating
miRNAs used in clinical diagnosis [27]. The relative contri-
bution to assay imprecision from components including intra
and inter-assay imprecision, miRNA extraction, reverse tran-
scription, real-time PCR, and normalisation to spiked or
internal-control miRNAs has yet to be established.
Potential use of circulating miRNAs in the athlete
biological passport
The fight against doping is mainly based on direct detection of
a prohibited substance in an athlete’s biological sample. Some
methods, including the ABP, also use indirect markers [32].
The ABP is a new tool, which has immense potential in the
current climate of rapidly advancing biomarker discovery
[32]. Doping induces physiological changes that enhance
performance. In the same way that disease-related biomarkers
are invaluable tools that assist physicians in the diagnosis of
pathology, specific biomarkers can be used to detect doping.
In 2008, the haematological module of the ABP was the
first to be implemented by the International Cycling Union
[33]. Biomarkers related to the haematopoietic system
(haemoglobin concentration, reticulocytes) are monitored
over time and analysed by use of mathematical models that
quantify individual variation to identify patterns that raise
suspicion of blood doping (e.g. ESA and autologous blood
transfusion) [31].
The underlying principle of the ABP is the use of informa-
tion from biological tests as indirect evidence to detect doping.
Fig. 2 Suggested strategy for
investigating use of circulating
miRNA-based blood biomarkers
to detect abuse of doping
compounds
Table 1 Advantages of using circulating miRNAs in the athlete biolog-
ical passport
Step Advantages of circulating miRNAs
Collection Similar to guidelines used for the
haematological module of the ABP
Transport High stability during transport
Analysis Long time period for detection
Correlation with blood-property variables
qPCR technology enables multiplexing analysis
Multiple quality controls could be easily added
Storage High stability during storage in EDTA–plasma
Not sensitive to unregulated room-temperature
storage (up to 10 years)
Stability in plasma subjected to multiple freeze–thaw cycles
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For this reason, a stringent process of sample collection,
transport, and data analysis has been put into place to guaran-
tee objective and reliable use of this tool [34]. This is of
particular importance because blood is a living tissue that
undergoes permanent changes over time; these changes must
be limited as much as possible, either by using standardised
procedures or by taking these changes into account in evalu-
ation of the data.
Circulating miRNAs have been investigated as potential
biomarkers for detection of blood doping, and could therefore
be incorporated into the adaptive model of the ABP. Among
the advantages ofmiRNAs as biomarkers is their high stability
in blood (Table 1), which enables detection over a longer time
period. Furthermore, in contrast with haematological vari-
ables, miRNAs are not affected by environmental factors,
for example inadequate storage during transport of the blood
samples [35]. Thus, use of miRNAs could reduce difficulties
caused by the extensive documentation regarding transport
and storage of samples. cDNA samples are also highly stable
under different storage conditions [36].
Blood samples included in haematological modules of the
ABP are analysed in WADA-accredited laboratories, where
strict quality-control criteria are applied to provide analysis of
forensic quality. Blood-variable analyses are performed by use
of automated blood-cell counters, and haematological vari-
ables could be correlated with miRNA measurements. Circu-
lating miRNAs could be analysed by use of qPCR. miRNA
qPCR is a well-established, robust, and reproducible method
with several important advantages, including high sensitivity
and specificity, potential for target multiplexing, and low
RNA input requirements, all of which facilitate expression
analysis, even for anti-doping samples with a limited amount
of material [28]. This method has already been implemented
in many diagnostic laboratories, and routine procedures are
well established. Quality control could easily be included at
every step to monitor sample haemolysis and extraction, re-
verse transcription, and qPCR efficiency, and such controls
could be used as normalisation factors [28]. Incorporation of
quality controls eliminates within-subject variation, increasing
the efficiency of the evaluation of biological data.
To validate and implement new biomarkers in the ABP, a
rigorous procedure must be followed. For the haematological
module of the ABP it has been possible to take advantage of
experience gained over many years with biomarkers including
haematocrit and haemoglobin. Schumacher et al. revealed that
haemoglobin concentration has significant diurnal and
exercise-related variation [37]. The same group observed that
a percentage of reticulocytes is modified by both long-term
and short-term exercise [38]. All these observations are al-
ready used for interpreting athlete blood-profile analyses. For
circulating miRNA, few data exist regarding external and
environmental factors that could interfere with miRNA mea-
surements in blood. Nevertheless, Baggish et al. revealed that
exercise can affect some types of circulating miRNA, includ-
ing those involved in inflammation (miR-146). Interestingly,
miRNAs involved in heart and skeletal muscle physiology
(miR-133a) and adaptation to hypoxia and ischaemia (miR-
210) did not vary in response to exercise [39].
Other confounding factors in the interpretation of miRNA
measurements should be investigated. As an example, the
effect of altitude and of use of hypoxic chambers on circulat-
ing miRNA levels should be studied, and the effect of the
circadian cycle on miRNA measurements should be investi-
gated. Unlike haemoglobin, circulating miRNAs were discov-
ered in 2008. Therefore additional studies from different dis-
ciplines, for example diagnosis of diseases for which circulat-
ing miRNAs have been tested as blood-related biomarkers,
should be used in the interpretation of longitudinal measure-
ments of miRNAs in the context of the ABP.
Outlook
Many elements contribute to the enormous potential of circu-
lating miRNAs as a class of ideal anti-doping biomarkers.
CirculatingmiRNAs are very stablemolecules, which are well
preserved under harsh conditions and resistant to RNase ac-
tivity. They are easily accessible, can be sampled in a relative-
ly non-invasive manner, and can be readily measured by use
of simple qPCR technology. Longitudinal measurement of
circulating miRNAs in the context of the ABP should be a
suitable way of using these new biomarkers in anti-doping.
Circulating miRNA research is still in its early stages, and
further work must be done to characterise the potential con-
founding factors affecting these biomarkers. As a result of the
plethora of data supporting the clinical use of miRNAs as
biomarkers for diseases, robust and reproducible tests for use
in patient treatment decisions are currently being developed.
The increasing clinical knowledge of these next-generation
biomarkers could be easily extrapolated to anti-doping.
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